Search results for

Levison Wood, who previously walked the length of the Nile River, has now trekked 1,700 miles, from Afghanistan to Bhutan, along the Himalayan mountain range.

Jane Sherron De Hart's biography sheds light on personal and professional challenges Ginsburg faced on the way to the top and puts the Supreme Court justice's life in context.

"Everybody's got to get out there and find the piece that they can do," the Democratic Massachusetts senator says. She talks to NPR's Audie Cornish about her new book, the middle class and activism.

Naomi Alderman's new novel imagines a world in which women suddenly pose a physical threat to men. Alderman says it was gratifying to imagine how characters might use that power to fight back.

Co-host Steve Inskeep talks to NPR's Frank Langfitt about Monday's earthquake in China. Langfitt has covered China and spent more than five years in the country as a correspondent for the Baltimore Sun.

Eight Democratic presidential candidates participate in a debate in New Hampshire. Sen. Hillary Clinton, the top contender, was politely pressed by rivals. She did her best to avoid being pinned down on questions about Iran, Social Security and baseball.

New numbers out Wednesday are expected to show the inflation rate in June was just over 3%. That's a big improvement from this time last year, when inflation topped 9%.

Sen. Hillary Clinton is scheduled to testify Tuesday before the Senate Foreign Relations Committee, which will decide whether to recommend to the full Senate that she be the next secretary of state. Clinton is expected to face tough questions from the committee's right flank, but not any major hurdles to confirmation.

Treasury Secretary Henry Paulson and Federal Reserve Chairman Ben Bernanke testified before the Senate Banking Committee Tuesday about the $700 billion rescue plan for the financial sector. They stressed that it was urgent that lawmakers pass the bill this week. Many committee members were not swayed.

Researchers analyzing recent drug spending in the U.S. say that high-priced drugs for rare diseases aren't having a widespread or significant effect on overall health care spending.